[HTML][HTML] Phase II trial of imatinib in AIDS-associated Kaposi's sarcoma: AIDS Malignancy Consortium Protocol 042

HB Koon, SE Krown, JY Lee, K Honda… - Journal of clinical …, 2014 - ncbi.nlm.nih.gov
HB Koon, SE Krown, JY Lee, K Honda, S Rapisuwon, Z Wang, D Aboulafia, EG Reid
Journal of clinical oncology, 2014ncbi.nlm.nih.gov
Purpose Kaposi's sarcoma (KS) is a disease of multifocal vascular proliferation that requires
infection with KS herpes virus (KSHV/HHV-8). Activation of the c-kit and platelet-derived
growth factor (PDGF) receptors by autocrine/paracrine mechanisms follows endothelial cell
KSHV infection. In a pilot study, imatinib, a c-kit/PDGF-receptor inhibitor, induced partial
regression of AIDS-associated KS (AIDS-KS) in five of 10 patients.
Abstract
Purpose
Kaposi's sarcoma (KS) is a disease of multifocal vascular proliferation that requires infection with KS herpes virus (KSHV/HHV-8). Activation of the c-kit and platelet-derived growth factor (PDGF) receptors by autocrine/paracrine mechanisms follows endothelial cell KSHV infection. In a pilot study, imatinib, a c-kit/PDGF-receptor inhibitor, induced partial regression of AIDS-associated KS (AIDS-KS) in five of 10 patients.
ncbi.nlm.nih.gov